PT1254121E - Preparacao de sulfonamidas - Google Patents

Preparacao de sulfonamidas

Info

Publication number
PT1254121E
PT1254121E PT00903628T PT00903628T PT1254121E PT 1254121 E PT1254121 E PT 1254121E PT 00903628 T PT00903628 T PT 00903628T PT 00903628 T PT00903628 T PT 00903628T PT 1254121 E PT1254121 E PT 1254121E
Authority
PT
Portugal
Prior art keywords
lower alkyl
hydrogen
hydroxy
alkoxy
alkyl
Prior art date
Application number
PT00903628T
Other languages
English (en)
Inventor
Bradley S Dehoff
Peter J Harrington
Hiralal N Khatri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1254121E publication Critical patent/PT1254121E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69Benzenesulfonamido-pyrimidines
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT00903628T 2000-01-25 2000-01-25 Preparacao de sulfonamidas PT1254121E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00903628A EP1254121B1 (en) 2000-01-25 2000-01-25 Preparation of sulfonamides
PCT/EP2000/000556 WO2001055120A1 (en) 2000-01-25 2000-01-25 Preparation of sulfonamides

Publications (1)

Publication Number Publication Date
PT1254121E true PT1254121E (pt) 2006-06-30

Family

ID=8163805

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00903628T PT1254121E (pt) 2000-01-25 2000-01-25 Preparacao de sulfonamidas

Country Status (13)

Country Link
EP (1) EP1254121B1 (pt)
JP (1) JP3751882B2 (pt)
KR (1) KR100495550B1 (pt)
CN (1) CN1178921C (pt)
AT (1) ATE316963T1 (pt)
AU (1) AU2000225442A1 (pt)
CA (1) CA2397258C (pt)
DE (1) DE60025803T2 (pt)
DK (1) DK1254121T3 (pt)
ES (1) ES2255973T3 (pt)
MX (1) MXPA02007192A (pt)
PT (1) PT1254121E (pt)
WO (1) WO2001055120A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2686457A1 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Novel polymorphic forms
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
AU2008315757A1 (en) * 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
KR20100113542A (ko) * 2008-01-01 2010-10-21 시플라 리미티드 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
CA2712860C (en) * 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CN101279948B (zh) * 2008-03-14 2010-08-11 苏州博鸿化工技术有限公司 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
CN102272108A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
JP2012523444A (ja) * 2009-04-13 2012-10-04 サンド・アクチエンゲゼルシヤフト 内皮受容体アンタゴニスト(ボセンタン)を調製するための方法
EP2368884A1 (en) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Process for the preparation of bosentan
CN103153964B (zh) 2010-10-01 2016-10-05 Zach系统股份公司 制备波生坦一水合物及其中间体的方法
JP2015503555A (ja) * 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR102004422B1 (ko) * 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
CN114907275A (zh) * 2022-04-29 2022-08-16 武汉工程大学 一种波生坦的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (pt) * 1992-12-10 1996-10-01 Hoffmann La Roche
CA2207100C (en) * 1994-12-28 2008-02-19 Kowa Co., Ltd. Pyrimidine derivatives
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US5883092A (en) * 1995-09-06 1999-03-16 Kowa Co., Ltd. Pyrimidine derivatives as endothelin antagonists

Also Published As

Publication number Publication date
EP1254121B1 (en) 2006-02-01
WO2001055120A1 (en) 2001-08-02
CA2397258A1 (en) 2001-08-02
KR100495550B1 (ko) 2005-06-16
MXPA02007192A (es) 2002-12-09
JP2003520857A (ja) 2003-07-08
JP3751882B2 (ja) 2006-03-01
KR20020070511A (ko) 2002-09-09
CA2397258C (en) 2007-07-03
EP1254121A1 (en) 2002-11-06
AU2000225442A1 (en) 2001-08-07
ATE316963T1 (de) 2006-02-15
CN1425007A (zh) 2003-06-18
ES2255973T3 (es) 2006-07-16
CN1178921C (zh) 2004-12-08
DE60025803D1 (de) 2006-04-13
DK1254121T3 (da) 2006-06-12
DE60025803T2 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
PT1254121E (pt) Preparacao de sulfonamidas
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
KR950702960A (ko) 레트로바이러스 프로테아제 저해제로서 유용한 히드록시에틸아미노 술폰아미드(hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
CY1107710T1 (el) Εκκριματαγωγa αυξητικhς ορμoνης
DK0699191T3 (da) Sulfonamider og derivater deraf, der modulerer aktiviteten af endotelin
AR241528A1 (es) Un procedimiento para la preparacion de n-(3- o 4-((alquilamino)alquil)-fenil)alcansulfonamidas y sus sales.
CA2081970A1 (en) Hiv protease inhibitors useful for the treatment of aids
ATE53023T1 (de) 5-acylamido-1-aryl-pyrazole.
ATE231149T1 (de) (1,8)-naphthyridinderivate derivate mit antiviraler wirkung
SE8900192L (sv) Dideoxididehydrokarbocykliska nukleosider
FI935517A0 (fi) Fenoxi- och fenoxialkylpiperidiner som virusmotverkande medel
DK0533790T3 (da) Hidtil ukendt saltform af 5-difluormethoxy-2-((3,4-dimethoxy-2-pyridyl)methylsulfinyl)-1H-benzimidazol
TR200000993T2 (tr) Endotelin antagonistleri.
UA35550C2 (uk) Похідні урацилу, що проявляють гербіцидну активність
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
EA200400117A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов, обладающие антивирусной активностью, способ их получения (варианты) и способ лечения вирусной инфекции
DE69028006D1 (de) Verwendung von Polyaminderivaten zur Verstärkung der zellularen Immunität
FI973111A (fi) Substituoidut fenyyliyhdisteet endoteliiniantagonisteina
SE8300580L (sv) Substituerade 1,3,4-tiadiazolo (3,2-a)pyrimidiner och forfarande for deras framstellning
JP2005504846A5 (pt)
GB1509840A (en) Phenylsulphenylpiperazines
MXPA01008189A (es) Proceso para la preparacion de compuestos 6-)perfluoroalquil) uracilo a partir de compuestos de urea.